Transitional cell carcinoma expresses high levels of Fas ligand in vivo

BJU Int. 1999 Apr;83(6):698-702. doi: 10.1046/j.1464-410x.1999.00975.x.

Abstract

Objective: To characterize the Fas-Fas ligand system, a main apoptotic pathway, in transitional cell carcinoma (TCC) of the urinary bladder, by analysing the expression of Fas and Fas ligand (FasL) in TCC samples.

Materials and methods: Archival paraffin-embedded tissues from 37 patients with TCC were analysed by immunohistochemistry to determine Fas and FasL expression.

Results: Fas and FasL were detected on the cell surface and cytoplasm of respectively 34 (92%) and all cases analysed. The expression of Fas and FasL did not differ with the cytological grade of TCC.

Conclusion: The high expression of FasL in TCC, reported for the first time in the present study, suggests that FasL may contribute to the immune escape of TCC through killing Fas-bearing lymphocytes. Co-expression of Fas with FasL also suggests that TCC may have pathways resistant to Fas-mediated autocrine cell suicide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Transitional Cell / metabolism*
  • Fas Ligand Protein
  • Humans
  • Immunohistochemistry
  • Ligands
  • Membrane Glycoproteins / metabolism*
  • Neoplasm Proteins / metabolism*
  • Urinary Bladder Neoplasms / metabolism*
  • fas Receptor / metabolism*

Substances

  • FASLG protein, human
  • Fas Ligand Protein
  • Ligands
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • fas Receptor